Published in J Biol Chem on March 25, 1985
Activation of human complement serine-proteinase C1r is down-regulated by a Ca(2+)-dependent intramolecular control that is released in the C1 complex through a signal transmitted by C1q. Biochem J (1994) 0.85
Quantitative analysis of the interaction between immune complex and C1q complement subcomponent. The role of interdomain interactions in rabbit IgG in binding of C1q to immune precipitates. Biochem J (1987) 0.75
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol (1994) 4.24
Sequential flotation ultracentrifugation. Methods Enzymol (1986) 2.27
Marfan syndrome: abnormal alpha 2 chain in type I collagen. Proc Natl Acad Sci U S A (1981) 1.78
Cross-linking of collagen and elastin. Properties of lysyl oxidase. Biochemistry (1970) 1.77
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 1.71
Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron (1995) 1.70
Lysyl oxidase. Int Rev Connect Tissue Res (1979) 1.70
Conformational changes of the chromatin subunit. Proc Natl Acad Sci U S A (1978) 1.66
Cloning and expression of apolipoprotein B, the major protein of low and very low density lipoproteins. Proc Natl Acad Sci U S A (1985) 1.65
X-linked cutis laxa: defective cross-link formation in collagen due to decreased lysyl oxidase activity. N Engl J Med (1980) 1.62
Human apolipoprotein B: partial amino acid sequence. FEBS Lett (1984) 1.54
Biosynthesis of collagen crosslinks: increased activity of purified lysyl oxidase with reconstituted collagen fibrils. Proc Natl Acad Sci U S A (1974) 1.52
Native cross-links in collagen fibrils induce resistance to human synovial collagenase. Biochem J (1979) 1.45
Circulating lipoproteins. Annu Rev Biochem (1969) 1.30
Ultrastructure of the first component of human complement: electron microscopy of the crosslinked complex. Proc Natl Acad Sci U S A (1982) 1.30
Genetic control of lipid transport in mice. I. Structural properties and polymorphisms of plasma lipoproteins. J Biol Chem (1983) 1.29
Collagen cross-linking. Enzymatic synthesis of lysine-derived aldehydes and the production of cross-linked components. J Biol Chem (1970) 1.27
Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res (1988) 1.26
Molecular weights of apoprotein B obtained from human low-density lipoprotein (apoprotein B-PI) and from rat very low density lipoprotein (apoprotein B-PIII). Biochemistry (1985) 1.26
Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond. Proc Natl Acad Sci U S A (1979) 1.19
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol (1996) 1.18
Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest (1995) 1.17
Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. J Clin Oncol (1985) 1.17
Collagen cross-linking. Purification and substrate specificity of lysyl oxidase. J Biol Chem (1976) 1.15
Testing the 'preliminary criteria for classification of SLE'. Ann Rheum Dis (1973) 1.14
Aortic aneurysm in Marfan's syndrome: changes in the ultrastructure and composition of collagen. J Anat (1979) 1.14
Stability and purification of lysyl oxidase. Arch Biochem Biophys (1974) 1.12
Biochemical and immunochemical study of lysyl oxidase in experimental hepatic fibrosis in the rat. Proc Natl Acad Sci U S A (1978) 1.10
Semi-flexible joint in the C1q subunit of the first component of human complement. J Mol Biol (1981) 1.08
Antigen valence and Fc-localized secondary forces in antibody precipitation. Mol Immunol (1980) 1.08
A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol (1986) 1.06
Activation of the first component of complement. Annu Rev Immunol (1987) 1.06
On the inhibition of lysyl oxidase by -aminopropionitrile. Biochem Biophys Res Commun (1972) 1.06
Human apolipoprotein B: identification of cDNA clones and characterization of mRNA. Nucleic Acids Res (1985) 1.03
The mechanism of activation of the first component of complement by a univalent hapten-IgG antibody complex. J Immunol (1977) 1.03
Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference. J Biol Chem (1992) 1.02
Collagen cross-linking. Synthesis of collagen cross-links in vitro with highly purified lysyl oxidase. J Biol Chem (1976) 1.02
Measurement of the association constants of the complexes formed between intact C1q or pepsin-treated C1q stalks and the unactivated or activated C1r2C1s2 tetramers. Mol Immunol (1983) 1.02
Segmental flexibility of immunoglobulin G antibody molecules in solution: a new interpretation. Biochemistry (1981) 1.01
Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis. Cytokine (1991) 1.01
Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro. J Biol Chem (1977) 0.99
Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. J Lipid Res (1995) 0.97
Mapping apolipoprotein B on the low density lipoprotein surface by immunoelectron microscopy. J Biol Chem (1991) 0.97
Intra-arterially administered reserpine and saline in scleroderma. Arch Intern Med (1974) 0.95
The temperature and pH dependence of conformational transitions of the chromatin subunit. Nucleic Acids Res (1979) 0.93
Cross-linking of collagen in the X-linked Ehlers-Danlos Type V. Biochem Biophys Res Commun (1979) 0.93
Anti-apoprotein B monoclonal antibodies detect human low density lipoprotein polymorphism. J Biol Chem (1984) 0.93
The pharmacologic regulation of interleukin-1 production: the role of prostaglandins. Cell Immunol (1988) 0.93
Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol (1994) 0.92
Nucleosome dissociation and transfer in concentrated salt solutions. Nucleic Acids Res (1979) 0.92
Dynamic aspects of antibody structure. Mol Immunol (1991) 0.92
Conformation and restricted segmental flexibility of C1, the first component of human complement. J Mol Biol (1983) 0.92
Rapid molecular weight estimates for low-density lipoproteins. Anal Biochem (1969) 0.91
Stabilization of Z-DNA by polyarginine near physiological ionic strength. Nucleic Acids Res (1982) 0.91
Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst (1976) 0.89
A rotor speed dependent crossover in sedimentation velocities of DNA's of different sizes. Biochem Biophys Res Commun (1974) 0.89
Zone centrifugation. Adv Biol Med Phys (1967) 0.89
Fundamental mass-transport equations for zone sedimentation velocity. Biochemistry (1965) 0.89
Anomalies in sedimentation. V. Chains at high fields, practical consequences. Biophys Chem (1976) 0.89
The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds. J Lipid Res (1999) 0.88
Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology (1994) 0.88
Apolipoprotein B: the Ag(a1/d) immunogenetic polymorphism coincides with a T-to-C substitution at nucleotide 1981, creating an Alu I restriction site. Arteriosclerosis (1988) 0.87
Polydispersity of human low-density lipoproteins. Ann N Y Acad Sci (1969) 0.87
A stability criterion for the measurement of diffusion coefficients in the zonal ultracentrifuge. Biochem Biophys Res Commun (1971) 0.87
Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering. Biochemistry (1995) 0.86
Bsp 12861 restriction fragment length polymorphism detects Ag(c/g) locus of human apolipoprotein B in all 17 persons studied. Arteriosclerosis (1989) 0.86
Stoichiometry and sedimentation properties of the complex formed between the C1q and C1r2C1s2 subcomponents of the first component of complement. J Immunol (1981) 0.86
Physical properties of recombinant apolipoprotein(a) and its association with LDL to form an LP(a)-like complex. Biochemistry (1993) 0.86
Identification of the ancestral haplotype for apolipoprotein B suggests an African origin of Homo sapiens sapiens and traces their subsequent migration to Europe and the Pacific. Proc Natl Acad Sci U S A (1991) 0.85
The free energy of angular position of the Fab arms of IgG antibody. Mol Immunol (1980) 0.85
Zone centrifugation in a cesium chloride density gradient caused by temperature change. Biophys J (1965) 0.85
Immunoglobulin M possesses two binding sites for complement subcomponent C1q, and soluble 1:1 and 2:1 complexes are formed in solution at reduced ionic strength. J Biol Chem (1985) 0.85
A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J Lipid Res (1997) 0.85
A theory of bivalent antibody-bivalent hapten interactions. Immunochemistry (1973) 0.85
Identification of the base substitution responsible for the Ag(x/y) polymorphism of apolipoprotein B-100. Arterioscler Thromb (1991) 0.84
Bivalent hapten-antibody interactions--1. A comparison of water soluble and water insoluble bivalent haptens. Immunochemistry (1975) 0.84
Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide. J Immunol (1993) 0.84
Conformation of apolipoprotein B after lipid extraction of low density lipoproteins attached to an electron microscope grid. J Lipid Res (1989) 0.83
Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q. J Immunol (1986) 0.83
Oligomerization of a 45 kilodalton fragment of diphtheria toxin at pH 5.0 to a molecule of 20-24 subunits. Biochemistry (1997) 0.83
Very low density lipoproteins: surface-volume changes during metabolism. J Theor Biol (1970) 0.82
Anomalies in sedimentation. 3. A model for the inherent instability of solutions of very large particles in high centrifugal fields. Biopolymers (1973) 0.82
Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex. Biochemistry (1992) 0.82
A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor. J Immunol (1988) 0.82
Measurement of macromolecular interactions between complement subcomponents C1q, C1r, C1s, and immunoglobulin IgM by sedimentation analysis using the analytical ultracentrifuge. J Biol Chem (1991) 0.81
Effects of limited denaturation by heat on the dynamic conformation of equine immunoglobulin M antibody and on interaction with antigen and complement. Biochemistry (1981) 0.81
Electron microscopic and hydrodynamic studies of protein A-immunoglobulin G soluble complexes. J Immunol (1984) 0.81
Bivalent hapten-antibody interactions--11. Bivalent haptens as probes of combining site depth. Immunochemistry (1975) 0.81
A model for the formation and interconversion of protein A-immunoglobulin G soluble complexes. J Immunol (1984) 0.81
Two DNA restriction fragment length polymorphisms associated with Ag(t/z) and Ag(g/c) antigenic sites of human apolipoprotein B. Arteriosclerosis (1987) 0.81
Angiogenesis in progressive systemic sclerosis. N Engl J Med (1972) 0.81
Human apolipoprotein B: chromosomal mapping and DNA polymorphisms of hepatic and intestinal species. Somat Cell Mol Genet (1986) 0.81
Expression and characterization of a 159 amino acid, N-terminal fragment of human complement component C1s. Mol Immunol (1997) 0.81